Efficacy and safety of apatinib for the treatment of advanced or recurrent cervical cancer: a single-arm meta-analysis among Chinese patients
Loading...
Authors
Huang, Da
He, Qionghua
Zhai, Lingyun
Shen, Jiayu
Jing, Fei
Chen, Huanhuan
Zhu, Xiaoqing
Zhou, Jianwei
Issue Date
2022-08-11
Type
Article
Language
en_US
Keywords
Apatinib , Recurrent/Metastatic Cervical Cancer , Objective Response Rate , Disease Control Rate , Adverse Events
Alternative Title
Abstract
Background: Although various effective compounds for the second- and third-line treatment of advanced or recurrent cervical cancer improved the overall survival, the optimal regimen remains controversial. Previous studies revealed that apatinib had extensive anti-tumor activities. However, almost all studies on apatinib in recurrent cervical cancer are non-randomized controlled trials with small sample sizes, different first-line treatments, and uncontrolled statistical analysis, which may result in a lack of effective metrics to evaluate the efficacy and safety of apatinib. Here, this meta-analysis aims to evaluate the efficacy and safety of apatinib in patients with advanced or recurrent cervical cancer.
Methods: PubMed, Embase, the Cochrane Library, and Web of Science databases were systematically searched for relevant studies. Outcomes including overall response rate (ORR), disease control rate (DCR), progression-free survival (PFS), overall survival (OS), and adverse events (AEs) were extracted for further analysis.
Results: Seven studies involving 243 patients were enrolled in this meta-analysis. In terms of tumor response, the pooled ORR and DCR were 22.9% and 68.6%, respectively. With regard to survival analysis, the pooled PFS and OS were 5.19 months and 10.63 months, respectively. The most common treatment-related adverse events of apatinib were hand–foot syndrome (all grade: 39.6%, ≥grade III: 7.5%), hypertension (all grade: 34.5%, ≥grade III: 9.2%), and fatigue (all grade: 28.0%, ≥grade III: 5.1%).
Conclusions: In summary, this meta-analysis demonstrated that apatinib has promising efficacy and safety for patients with advanced or recurrent cervical cancer.
Description
Citation
Huang, D., He, Q., Zhai, L., Shen, J., Jing, F., Chen, H., Zhu, X., & Zhou, J. (2022). Efficacy and Safety of Apatinib for the Treatment of Advanced or Recurrent Cervical Cancer: A Single-Arm Meta-Analysis Among Chinese Patients. Frontiers in pharmacology, 13, 843905. https://doi.org/10.3389/fphar.2022.843905
Publisher
Frontiers in Pharmacology